会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明授权
    • Integrity-enhanced thermoelectrics
    • 完整的增强型热电
    • US5209786A
    • 1993-05-11
    • US594850
    • 1990-10-09
    • Jonathan L. RolfeJohn S. Beaty
    • Jonathan L. RolfeJohn S. Beaty
    • H01L35/32
    • H01L35/32
    • Disclosed are integrity-enhanced thermoelectric devices and methods of their preparation. Such devices have the following characteristics: (1) there is, on average, no greater than about 10% incidence of function loss (failure) of the device on application to the device of a substantial impact or distortion force or corrosion exposure, and (2) the device have at least about 85% of the thermal performance of thermoelectric devices without integrity enhancement (i.e., thermal conductivity across the integrity-enhanced devices is significantly less than 0.0021 Cal-Cm/Cm.sup.2 Sec .degree.C., and is less than or equal to about 0.0015 Cal-Cm/Cm.sup.2 Sec .degree.C.; empirically expressed as maintenance of at least a 40.degree. C. temperature differential over the intra-plate distance which is about 3/16 to about 1/4 of an inch.). Integrity enhancement techniques are described, including the method of embedding components of standard thermoelectric devices in syntactic foam materials, such as those formed of resins and balloon elements.
    • 5. 发明授权
    • Drug dispensing wound dressing
    • 药物分配伤口敷料
    • US4614787A
    • 1986-09-30
    • US670810
    • 1984-11-13
    • Michael SzycherDonald J. DempseyJonathan L. Rolfe
    • Michael SzycherDonald J. DempseyJonathan L. Rolfe
    • A61F13/15A61L15/26A61L15/44C08G18/10A61F13/00
    • A61L15/44A61L15/26A61F2013/530007A61L2300/402A61L2300/404A61L2300/41A61L2300/418
    • The disclosed wound dressings have a drug dispersed throughout a polyurethane matrix that is the reaction product of: (A) An isocyante terminated prepolymer formed by reaction of isophorone diisocyanate and a macroglycol and (B) a monomer containing hydroxyl and vinyl groups. The reaction product is a vinyl terminated polyurethane oligomer which is liquid at room temperature and which may be readily admixed with a pharmacoactive substance and a photosensitizer, formed into a film and cured by exposure to UV light without release of heat.In the most preferred embodiments the foregoing oligomer is codissolved in an organic solvent with a polyurethane polymer which is the reaction product of:dicyclohexyl methane diisocyanate;a polytetramethylene ether polyol having a molecular weight in the range of 1000-3000 daltons; and1,4-butane diol.That solution is then admixed with the pharmacoactive agent, formed into a film and cured.
    • 所公开的伤口敷料具有分散在整个聚氨酯基质中的药物,其是以下物质的反应产物:(A)通过异佛尔酮二异氰酸酯和大分子二醇反应形成的异氰酸酯封端的预聚物和(B)含有羟基和乙烯基的单体。 反应产物是在室温下为液体的乙烯基封端的聚氨酯低聚物,其可以容易地与药物活性物质和光敏剂混合,形成膜并通过暴露于UV光而不释放热而固化。 在最优选的实施方案中,上述低聚物与聚氨酯聚合物共同存在于有机溶剂中,所述聚氨酯聚合物是以下物质的反应产物:二环己基甲烷二异氰酸酯; 分子量为1000-3000道尔顿的聚四亚甲基醚多元醇; 和1,4-丁二醇。 然后将该溶液与药物活性剂混合,形成膜并固化。